MedTrace Logo

A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

NCT05677438 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2024-06-28

No results posted yet for this study

Summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia

Conditions

Interventions

DRUG

CKD-498 dose#1

oral, once daily, 24 weeks

DRUG

CKD-498 dose#2

oral, once daily, 24 weeks

DRUG

CKD-498 dose#3

oral, once daily, 24 weeks

DRUG

Placebo of CKD-498 dose#1

oral, once daily, 24 weeks

DRUG

Placebo of CKD-498 dose#2

oral, once daily, 24 weeks

DRUG

Placebo of CKD-498 dose#3

oral, once daily, 24 weeks

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • ChangHun Huh, MD, PhD. · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2023-12-15
Completion
2023-12-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05677438 on ClinicalTrials.gov